People

The People

Grade: B. Governance here is clean on paper — fully independent board, no related-party transactions, strong clawback, meaningful ownership guidelines — but the tape shows a company under pressure: TSR has lagged the healthcare-equipment peer group by ~37 points over four years, activist investor Jana Partners is pushing to break up CooperVision and CooperSurgical, and Browning West has already placed a director (Walter Rosebrough) through a December 2025 cooperation agreement. The offset, and it is a real one, is that ten insiders — including the CEO twice — bought $2.52 million of stock on the open market in 2025 with zero sales. That is a rare, unambiguous signal of internal alignment even as outside capital is demanding structural change.

The People Running This Company

Albert G. White III — CEO. Joined Cooper in 2006 from KeyBanc Capital Markets, climbed through Investor Relations, Treasurer, Chief Strategy Officer, and CFO before taking the CEO job in 2018. He ran CooperSurgical as an EVP before becoming CEO — which is exactly the fact Jana Partners weaponized in its October 2025 campaign: the company's leader has never run the contact lens business that generates two-thirds of revenue. White has never held a line role at a vision peer. He does sit on Evolus (EOLS) as Compensation Committee Chair.

Brian G. Andrews — CFO. Insider hire, has been Treasurer since 2013 and CFO since 2018. Columbia econ, ex-KeyBanc like White. No prior public-company CFO experience before Cooper, but ~20-year tenure.

Daniel G. McBride — COO/GC. Lawyer (Stanford Law, Latham & Watkins M&A practice) who has been COO since 2013 and took the General Counsel title back in October 2025 in what looks like a consolidation move. Largest shareholder on the executive team after White (685,784 beneficial shares, mostly via options).

Holly R. Sheffield — President, CooperSurgical. Ex-UBS Global Head of Medical Tech (2009–2018). Banker in the line role — she architected many of the CooperSurgical deals, then was promoted to run the division. Strong dealmaker resume; operating track record is what Jana is questioning.

Gerard H. Warner III — President, CooperVision. The only NEO with deep contact-lens operating history: 17 years at Bausch + Lomb before joining CooperVision in 2012. Runs the crown-jewel segment.

What They Get Paid

Does the pay work? Total CEO compensation of $16.05M sits inside the peer group (Agilent, Illumina, Align, DexCom, Edwards, Zimmer Biomet, etc., $1.8B–$7.4B revenue). The structure is textbook best-practice: 93% of White's target comp is performance-linked, 85% of the annual cash bonus depends on quantitative financial metrics (revenue, non-GAAP EPS, free cash flow), and PSUs have a three-year cliff tied to constant-currency EPS CAGR. Say-on-Pay passed with ~90% support at the 2024 meeting.

Where the math gets interesting is "Compensation Actually Paid." White's CAP collapsed from $39.8M in FY24 to $1.77M in FY25 — a 96% drop — because the stock price fell and his unvested equity is marked to market. That is the plan working: when TSR drops from $100 to $67 over four years, the realized pay drops with it. FY22 CAP was actually negative.

The CEO pay ratio is 331:1 ($16.05M vs. $48,540 median employee). That is above peer group medians but not unusual for a globally distributed medical device company with low-cost manufacturing.

Starting FY2026, the OCC is adding relative TSR vs. the S&P Healthcare Equipment Index as a 25% PSU weight — a direct response to the last four years of peer underperformance and exactly what a proxy advisor would ask for.

Are They Aligned?

Ownership and Control

No founder, no dual-class, no controlling shareholder. Index funds dominate the register — Vanguard (11.6%), BlackRock (7.1%), Capital World (5.5%). All 13 directors and officers together own 2.08%. The CEO owns 1% outright. This is a pure institutional-owned US large-cap. The control lever is proxy voting — exactly the lever Jana is now testing.

Insider Buying vs Selling — The Strongest Signal on the Page

The September buys came right after the stock fell 12.85% on the Q3 earnings call when Cooper cut full-year guidance. The December buys came after Jana Partners announced its activist position. Two things both true: management is not selling into the controversy, and they are spending real personal cash at prices that are still well below the 52-week high.

Dilution and Capital Return

In FY2025, Cooper repurchased $290.1M (4.1M shares) at an average of $69.30 — into the teeth of the sell-off. The Board expanded authorization to $2 billion in September 2025. Q1 FY26 saw another $92.5M at $82.04. Management is using cash to shrink the float even while funding the balance-sheet work (debt reduction, restructuring charges of ~$89M taken to deliver ~$50M of annual run-rate savings). This is disciplined capital allocation, not empire-building — it is a meaningful behavior change from the 2017–2024 stretch Jana criticized as "siphoning cash into CooperSurgical."

Related-Party Transactions

The 2026 proxy is explicit: zero related-party transactions requiring disclosure during fiscal 2025. The policy is tight (Audit Committee pre-approval, KPMG audit review, clear carve-outs only for ordinary-course items). No pledging, no hedging, prohibited by policy. No stockholder rights plan ("poison pill"). Proxy access is standard.

Skin-in-the-Game Score

7 / 10. The CEO owns roughly $126M of stock at the recent $65 price (1.94M shares at 1% of the company), well above the 6× salary guideline ($7.1M) that the OCC just increased from 5×. All NEOs comply. Insider purchases in 2025 were decisive and collectively priced-in the downside. The score is not higher because (a) directors' individual holdings are small — several hold well under $1M — and (b) a large portion of "ownership" is in exercisable but in-the-money options rather than paid-for shares.

Board Quality

Strengths. Eight of nine directors are independent (all except CEO White). The Chair (Colleen Jay) is independent. Five of nine are women. All three standing committees are fully independent. Audit Committee chair (Teresa Madden) is a Fortune-300 retired CFO with an active CPA license; her committee includes a retired KPMG Audit Partner (Carbone). Compensation Committee is chaired by an ex-P&G Global Division President and includes an ex-public-company CEO (Kurzius) who doubled his company's market cap. The Browning West-placed director (Rosebrough, joined January 2026) is the real ringer: during his 14-year CEO tenure at STERIS, shareholders compounded at 18% annually versus 10% for the S&P 500, and he has explicit medical-device M&A and operational transformation experience.

Weaknesses. Two structural issues. First, Bob Weiss has been on the Board since 1996 and was CEO until 2018; classifying him as "independent" is technically correct under Nasdaq rules (he has been off the payroll more than three years) but functionally he is not an outsider — he hired White and built the current strategy. Second, no director attended the 2025 annual meeting of stockholders, which is a minor but telling signal on shareholder engagement. The "directors may not serve on more than three other public boards" rule is well-followed; the busiest director has two outside boards.

The Verdict

Grade: B.

Strongest positives. (1) Ten open-market insider buys in 2025 with zero sales, led by the CEO putting $1.49M of personal cash to work across two separate tranches — the sell-side's favorite insider signal. (2) Clean governance mechanics: independent Chair, fully independent committees, no related-party transactions, no poison pill, no dual-class, robust clawback, hedging/pledging prohibited, ownership guidelines just raised from 5× to 6× salary for the CEO. (3) Disciplined capital return — $383M repurchased in FY25 + Q1 FY26 at declining prices. (4) Real pay-for-performance — CEO CAP fell 96% in FY25 as TSR lagged peers, and FY26 equity will include a relative-TSR PSU component.

The real concerns. (1) Strategy credibility. Jana Partners' critique is economically serious: Cooper has deployed $3B into CooperSurgical since 2017, returns on capital have declined, and the CEO was the former head of CooperSurgical. The board signed off on every piece of that plan. (2) TSR underperformance. Cumulative TSR of $67 vs. peer group $104 over four years is not a rounding error — it is the reason activists are here. (3) Board refresh is reactive, not proactive. Rosebrough is a strong add, but he is there because Browning West demanded a seat. Left alone, the board added one director (Carbone) in four years.

Upgrade catalyst: public, specific, time-bound engagement on portfolio separation or on CooperSurgical ROIC improvement — i.e., the board moves from passive acceptance of Jana's thesis to driving the strategic review itself. Any of: formal strategic review announcement, sale of a non-core CooperSurgical asset, or a clean contact-lens operator added to the Board.

Downgrade catalyst: management publicly dismisses Jana's campaign, insider buying pattern reverses in 2026, or any governance erosion (renegotiated CEO package, added perquisites, or a poison pill in response to activism).